The per capita GDP phrase was deleted from the ICER threshold used in the economic evaluation process of the first stage of new drug benefits. Although it has been changed to refer to the results of the existing deliberation, the phrase GDP per capita has been deleted, and the application of ICER values, one of the pharmaceutical industry's long-cherished projects, remains to be seen.

On the 23rd, The HIRA unveiled the "Detailed Evaluation Criteria for Drugs Subject to Negotiation, such as New Drugs (Completed Amendment)." The revision of this standard includes the evaluation criteria deliberated and resolved at the 8th Pharmaceutical Benefit Appeal Committee held on September 3.

The HIRA